The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 27, 2021
Filed:
Apr. 04, 2016
Applicant:
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);
Inventor:
Scott Antonia, Land O'Lakes, FL (US);
Assignee:
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., Tampa, FL (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/15 (2015.01); C12N 7/00 (2006.01); A61K 35/761 (2015.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); A61K 48/00 (2006.01); A61K 45/06 (2006.01); C12N 15/86 (2006.01); A61K 31/203 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 39/001151 (2018.08); A61K 31/203 (2013.01); A61K 35/761 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); A61K 48/0066 (2013.01); C07K 14/4746 (2013.01); C07K 16/2827 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 35/15 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/545 (2013.01); A61K 2039/585 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12N 2710/10043 (2013.01);
Abstract
A method is disclosed for treating small cell lung cancer (SCLC) in a subject that involves administering to the subject a therapeutically effective amount of dendritic cells engineered to overexpress p53. In some embodiments, the method further involves administering to the subject a therapeutically effective amount of all-trans-retinoic acid (ATRA). The method can also involve administering to the subject a therapeutically effective amount of an immune checkpoint inhibitor.